Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECCE 327 for mild diabetes-related foot infection
ACTRN12623000056695Phase 2Terminated
- Sponsor
- Recce Pharmaceuticals Ltd
- Start
- Aug 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of RECCE 327 in Foot infection and diabetic foot infection (DFI) (2 arms), sponsored by Recce Pharmaceuticals Ltd. Primary endpoints: Change in diabetic foot wound scores with infection resolution and healing at day 28, Need for rescue therapy at day 28 and 1 more. Started Aug 2023; status: terminated.
02
Drugs
RECCE 327
03
Conditions
Foot infectiondiabetic foot infection (DFI)
Beyond the preview
Go deeper on ACTRN12623000056695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000056695.